Does Ceritinib Interact with Rifampin?
CDI records a major classification for Ceritinib and Rifampin. The stored summary is: Strong CYP3A4/P-gp inducer decreased systemic exposure of ceritinib, which may decrease efficacy of ZYKADIA. Avoid concurrent use. The mechanism involves cyp3a4/p-gp induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Ceritinib Class
- Kinase Inhibitor
- Rifampin Class
- Rifamycin Antibacterial
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A4/P-gp induction
What To Tell Your Doctor or Pharmacist
If you are taking Ceritinib and your doctor is considering prescribing Rifampin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider